2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173355
    RCB18350 3052630-27-7 98%
    RCB18350 is an antituberculosis agent that belongs to the class of isoxazole derivatives. RCB18350 has bacteriostatic activity and inhibits the growth of Mycobacterium tuberculosis with an MIC of 1.25 μg/mL. RCB18350 is effective against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) clinical isolates, slow-growing mycobacteria such as Mycobacterium bovis BCG and Mycobacterium avium.
    RCB18350
  • HY-173356
    Antiparasitic agent-26 98%
    Antiparasitic agent-26 (Compound 8) is an antiparasitic compound that potently inhibits the growth of Naegleria fowleri, with IC50 values of 22.87 μM (trophozoite stage) and 25.16 μM (cyst stage). Antiparasitic agent-26 exerts its antiparasitic activity by inducing programmed cell death, including cytoplasmic calcium accumulation, mitochondrial membrane potential collapse, ATP synthesis inhibition, ROS accumulation, and chromatin condensation. Antiparasitic agent-26 can be used in the research of primary amoebic meningoencephalitis (PAM).
    Antiparasitic agent-26
  • HY-173362
    SARS-CoV-2 Mpro-IN-39 98%
    SARS-CoV-2 Mpro-IN-39 (Compound 9d) is an inhibitor of the main protease (Mpro) of SARS-CoV-2, with an IC50 value of 5.94 µM, an EC50 value of 9.33 µM for inhibiting the replication of SARS-CoV-2 in Vero cells, and a cytotoxicity CC50 value of 289.63 µM. SARS-CoV-2 Mpro-IN-39 can be used in the research of the anti-COVID-19 field.
    SARS-CoV-2 Mpro-IN-39
  • HY-173375
    Mycobacterium Tuberculosis-IN-8 98%
    Mycobacterium Tuberculosis-IN-8 (Compound 6g) is a selective inhibitor of Mycobacterium tuberculosis (MTB) with an MIC value of 6.25 µg/mL against MTB H37Rv. Mycobacterium Tuberculosis-IN-8 shows potent antitubercular activities, inhibiting mycolic acid biosynthesis critical for bacterial cell wall integrity. Mycobacterium Tuberculosis-IN-8 is promising for research of antitubercular agents.
    Mycobacterium Tuberculosis-IN-8
  • HY-173402
    TPS1-IN-1
    TPS1-IN-1 (Compound O1) is a highly potent and broad-spectrum TPS1 inhibitor. TPS1-IN-1 with IC50s of 14.73 μM for MoTPS1 (TPS1 of M oryzae) and 59.99 μM for BcTPS1 (TPS1 of B cinerea), respectively. TPS1-IN-1 exerts a broad-spectrum fungicidal effect by interfering with spore germination, appressorium formation, and turgor pressure accumulation of fungi. TPS1-IN-1 has good safety and has the potential to be a novel fungicide candidate compound.
    TPS1-IN-1
  • HY-173417
    Antibacterial agent 275 98%
    Antibacterial agent 275 (Ⅲ1) is a antibacterial agent, with a λmax of 730 nm. Antibacterial agent 275 (Ⅲ1) can be used in the research for antimicrobial photodynamic therapy (aPDT).
    Antibacterial agent 275
  • HY-173421
    (H)S(OMe)-DFR-kbt 98%
    (H)S(OMe)-DFR-kbt (compound 9) is a potent and selective TMPRSS2 inhibitor with a Ki of 0.13 nM. (H)S(OMe)-DFR-kbt can be used in the study of SARS-CoV-2.
    (H)S(OMe)-DFR-kbt
  • HY-173426
    SARS-CoV-2 Mpro-IN-40 98%
    SARS-CoV-2 Mpro-IN-40 (compound 119) is an inhibitor of SARS-CoV-2 Mpro, with an IC50 value of 15.7 nM against Mpro Fret. SARS-CoV-2 Mpro-IN-40 exhibits low metabolic stability in human microsomes.
    SARS-CoV-2 Mpro-IN-40
  • HY-173428
    Antifungal agent 130 98%
    Antifungal agent 130 (Compound A7) is an orally active antifungal agent. Antifungal agent 130 has good antifungal activity against Candida albicans (MIC = 0.12 ng/mL) and Cryptococcus neoformans (MIC = 0.12 ng/mL) and has excellent antivirulence effect. Antifungal agent 130 exerts its antifungal effect by disrupting the iron homeostasis of fungal cells and inducing oxidative stress damage. Antifungal agent 130 can inhibit the formation of fungal virulence factors (such as biofilm, capsule, urease and melanin). Antifungal agent 130 has good antifungal effect and can be used in the study of drug-resistant fungal infections.
    Antifungal agent 130
  • HY-173429
    Herbicidal agent 10 98%
    Herbicidal agent 10 (compound 3s) is a potent herbicidal agent. Herbicidal agent 10 inhibits SvEPSPS with an IC50 of 7.8 μM.
    Herbicidal agent 10
  • HY-173448
    CDA-IN-4 466656-34-8 98%
    CDA-IN-4 (compound VS-24) is a chitin deacetylase (CDA) inhibitor. CDA-IN-4 shows a 61.2% protective effect against rice blast at a concentration of 100 μg/mL.
    CDA-IN-4
  • HY-173452
    DT-23 98%
    DT-23 is a potent antifungal agent with an MIC50 of 15 μg/mL. DT-23 inhibits recombinant Arg1 and Kcs1 with IC50s of 0.6 and 0.68 μM, respectively.
    DT-23
  • HY-173458
    NBTIs-IN-7 98%
    NBTIs-IN-7 (compound 276) is a novel bacterial topoisomerase (NBTIs) inhibitor. NBTIs-IN-7 induces both single- and double-strand DNA strand breaks in the presence of gyrase.
    NBTIs-IN-7
  • HY-173459
    N-0920 3108784-69-3 98%
    N-0920 is a potent TMPRSS2 inhibitor with an IC50 of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC50s values of 300 pM and 90 pM, respectively.
    N-0920
  • HY-173461
    Anti-Trypanosoma cruzi agent-7 2959033-89-5 98%
    Anti-Trypanosoma cruzi agent-7 (compound 1) is a potent Trypanosoma cruzi inhibitor with an EC50 of 1.26 µM. Anti-Trypanosoma cruzi agent-7 can be used in the study of Chagas disease.
    Anti-Trypanosoma cruzi agent-7
  • HY-173472
    MBL-IN-5 2876921-34-3 98%
    MBL-IN-5 is a metallo-β-lactamase (MBL) inhibitor. MBL-IN-5 inhibits three clinically relevant B1 subfamily MBLs (NDM-1, VIM-1, and IMP-1) with IC50s of 0.05  nM, 14  nM and 21 nM respectively. MBL-IN-5 remarkably enhances carbapenems’ effectiveness against MBL-producing clinical strains and significantly reduces the bacterial load in a neutropenic murine thigh infection model combined with the IPM antibiotic.
    MBL-IN-5
  • HY-173485
    SARS-CoV-2 Mpro-IN-41 98%
    SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively). SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM). SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research.
    SARS-CoV-2 Mpro-IN-41
  • HY-173490
    Antifungal agent 131 98%
    Antifungal agent 131 (compound A20) is an antifungal compound with a minimum inhibitory concentration (MIC) of 64 μg/mL. Antifungal agent 131 demonstrates excellent antifungal potential when used in combination with Fluconazole (HY-B0101).
    Antifungal agent 131
  • HY-173508
    EBOV entry-IN-1 98%
    EBOV entry-IN-1 (compound Hu7) is an EBOV entry inhibitor with an IC50 of 1.50 μM.
    EBOV entry-IN-1
  • HY-173511
    SARS-CoV-2 nsp13-IN-7 98%
    SARS-CoV-2 nsp13-IN-7 (Compound 6r) is a SARS-CoV-2 nsp13 inhibitor (IC50: 0.28 μM). SARS-CoV-2 nsp13-IN-7 interferes with the helicase function of nsp13 by binding to the 5' RNA site and ATP binding site of nsp13. SARS-CoV-2 nsp13-IN-7 can be used as a lead compound for the development of antiviral drugs targeting SARS-CoV-2 nsp13.
    SARS-CoV-2 nsp13-IN-7
Cat. No. Product Name / Synonyms Application Reactivity